Program Status
RecruitingPhase
Phase 2Prior Immunotherapy Allowed
NoCRC-directed Trial
YesDrugs
ABBV-400, Bevacizumab, fluorouracil, Folinic acid, IrinotecanTags
MSS/ MMRpComments
Phase II trial for patients with metastatic CRC who progressed on only one first-line systemic treatment (trial to consider before starting 2nd line treatment for the metastatic setting).
Only for MSS patients, no BRAF mutation allowed.
Combination of a novel agent at different doses, with different combinations of standard of care treatment.
ABBV-400: ADC (antibody-drug conjugate). C -Met–targeting antibody telisotuzumab conjugated to a potent topoisomerase 1 inhibitor (Top1i) payload.
Standard of care drugs used in combinations in this trial: Fluorouracil, Folinic Acid, Bevacizumab
Location | Location Status |
---|---|
United States | |
Highlands Oncology Group, PA /ID# 259424 Springdale, Arkansas 72762 |
Recruiting |
City of Hope National Medical Center /ID# 257576 Duarte, California 91010 |
Recruiting |
Northwestern University Robert H. Lurie Comprehensive Cancer Center /ID# 260563 Chicago, Illinois 60611-2927 |
Recruiting |
Fort Wayne Medical Oncology and Hematology- South Office /ID# 259601 Fort Wayne, Indiana 46804 |
Recruiting |
Community Health Network, Inc. /ID# 257078 Indianapolis, Indiana 46250-2042 |
Recruiting |
Duke Cancer Center /ID# 257236 Durham, North Carolina 27710-3000 |
Recruiting |
Medical University of South Carolina /ID# 258486 Charleston, South Carolina 29425 |
Recruiting |
MD Anderson Cancer Center /ID# 258713 Houston, Texas 77030 |
Recruiting |
Millennium Research and Clinical Development /ID# 257780 Houston, Texas 77090-3063 |
Recruiting |
Virginia Cancer Specialists - Fairfax /ID# 257261 Fairfax, Virginia 22031 |
Recruiting |
Belgium | |
Imelda Ziekenhuis /ID# 257082 Bonheiden, Antwerpen 2820 |
Recruiting |
AZ-Delta /ID# 257084 Roeselare, West-Vlaanderen 8800 |
Recruiting |
Israel | |
Tel Aviv Sourasky Medical Center /ID# 257090 Tel Aviv, Tel-Aviv 6423906 |
Recruiting |
Hadassah /ID# 257088 Jerusalem, Yerushalayim 91120 |
Recruiting |
Japan | |
Aichi Cancer Center Hospital /ID# 257286 Nagoya-shi, Aichi 464-8681 |
Recruiting |
National Cancer Center Hospital East /ID# 257282 Kashiwa-shi, Chiba 277-8577 |
Recruiting |
Kyoto University Hospital /ID# 257287 Kyoto-shi, Kyoto 606-8507 |
Recruiting |
Shizuoka Cancer Center /ID# 257288 Sunto-gun, Shizuoka 411-8777 |
Recruiting |
National Cancer Center Hospital /ID# 257284 Chuo-ku, Tokyo 104-0045 |
Recruiting |
Korea, Republic of | |
Chonnam National University Hwasun Hospital /ID# 258366 Hwasun-gun, Jeonranamdo 58128 |
Recruiting |
Seoul National University Hospital /ID# 257493 Seoul, Seoul Teugbyeolsi 03080 |
Recruiting |
Asan Medical Center /ID# 257845 Seoul, Seoul Teugbyeolsi 05505 |
Recruiting |
Samsung Medical Center /ID# 257571 Seoul, Seoul Teugbyeolsi 06351 |
Recruiting |
Yonsei University Health System Severance Hospital /ID# 257492 Seoul 03722 |
Recruiting |
Spain | |
Hospital Universitario Vall d'Hebron /ID# 257383 Barcelona 08035 |
Recruiting |
Hospital Universitario 12 de Octubre /ID# 257384 Madrid 28041 |
Recruiting |
Hospital Universitario HM Sanchinarro /ID# 258549 Madrid 28050 |
Recruiting |
Hospital Universitario Miguel Servet /ID# 257388 Zaragoza 50009 |
Recruiting |
Taiwan | |
Kaohsiung Chang Gung Memorial Hospital /ID# 257675 Kaohsiung City, Kaohsiung 833 |
Recruiting |
National Taiwan University Hospital /ID# 257639 Taipei City, Taipei 100 |
Recruiting |
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 257637 Kaohsiung 807 |
Recruiting |
National Cheng Kung University Hospital /ID# 257638 Tainan 704 |
Recruiting |
Taipei Veterans General Hosp /ID# 257636 Taipei 11217 |
Recruiting |
Linkou Chang Gung Memorial Hospital /ID# 257640 Taoyuan City 333 |
Recruiting |
Contacts
Inclusion Criteria
Inclusion Criteria:
* Diagnosis of histologically or cytologically confirmed unresectable metastatic colorectal cancer (mCRC).
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Exclusion Criteria
Exclusion Criteria:
* Harbor the BRAF V600E mutation.
* dMMR+/MSI-H.
* Progressed on only one first-line (1L) systemic treatment of combination chemotherapy in the metastatic setting with or without targeted therapy.
* Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400.